PLASMA MYELOPEROXEDASE LEVEL IN PATIENTS WITH CHRONIC LIVER DISEASE
|Full paper||Not Available|
Myeloperoxidase (MPO) is a heme protein present in the granules of neutrophils and monocytes. The aim of this work was to study plasma level of myeloperoxidase in different chronic liver diseases. The present work was can-led out on 54 patients of chronic liver disease, admitted to Benha university hospital and 18 healthy individuals served as controL The study included 4 groups: Twenty seven patients were diagnosed as bilharzial liver fibrosis (group 1). Fifteen patients were diagnosed as posthepatitic cirrhosis (group II). Twelve patients were diagnosed as chronic hepatitis (group III). Eighteen healthy individuals (control group). All studied patients were subjected to complete medical history and flail clinical examination, abdominal ultrasonography and/or abdominal CT scanning and sonar guided liver biopsy for histological examination. All studied and control groups were subjected to liver function tests, complete blood picture, prothrombin time and estimation of plasma myeloperoxidase level by ELIISA technique. The results showed that plasma MPO level was markedly higher in both bilharzial liver fibrosis and post hepatitic cirrhosis than chronic hepatitis group and correlated positively with lactate dehydrogenase level and alkaline phosphatase level, and negatively correlated with albumin, total leucocytic count and neutrocyte count. The results also showed that MPO was significantly higher in patients with chronic liver diseases complicated with splenomegaly, oesophageal vatices and in patients complicated with hepatocellular carcinoma but showed no significant difference in patients with ascites than those without ascites. It was concluded that high plasma levels of 114P0 in liver cirrhosis or fibrosis could be added as a possible marker of hypersplenism.